Table 3.

Relationships Between Hospital-Level Process Measures and Patient-Level Outcomes^*

Measure	Unadjusted		Adjusted
	HR (95% CI)	P Value	HR (95% CI)	P Value
Mortality at 1 Year
Any beta-blocker	0.95 (0.90–1.00)	.03	0.94 (0.90–0.98)	.004
Evidence-based beta-blocker	0.95 (0.92–0.99)	.01	0.95 (0.92–0.98)	.004
Warfarin	0.99 (0.93–1.04)	.62	0.97 (0.92–1.03)	.33
Aldosterone antagonist	0.94 (0.91–0.98)	.006	0.94 (0.91–0.98)	.006
ICD	0.93 (0.87–0.99)	.02	0.92 (0.87–0.98)	.007
Disease management	1.01 (0.99–1.03)	.24	1.01 (0.99–1.03)	.21
Mortality at 60 Days
Any beta-blocker	0.95 (0.89–1.03)	.20	0.95 (0.89–1.02)	.20
Evidence-based beta-blocker	0.95 (0.89–1.02)	.14	0.95 (0.88–1.02)	.13
Warfarin	0.94 (0.87–1.03)	.18	0.93 (0.86–1.01)	.07
Aldosterone antagonist	0.93 (0.86–0.99)	.03	0.92 (0.86–1.00)	.04
ICD	0.92 (0.82–1.03)	.14	0.90 (0.81–1.00)	.04
Disease management	1.01 (0.97–1.05)	.62	1.01 (0.97–1.05)	.55
Cardiovascular Readmission at 1 Year
Any beta-blocker	0.98 (0.93–1.03)	.47	0.97 (0.92–1.02)	.21
Evidence-based beta-blocker	0.96 (0.92–1.00)	.03	0.95 (0.91–0.99)	.008
Warfarin	1.00 (0.96–1.04)	.87	1.00 (0.97–1.04)	.88
Aldosterone antagonist	0.99 (0.96–1.03)	.73	0.99 (0.95–1.02)	.48
ICD	1.06 (1.01–1.12)	.01	1.07 (1.02–1.13)	.005
Disease management	1.01 (1.00–1.03)	.13	1.01 (1.00–1.03)	.06
Cardiovascular Readmission at 60 Days
Any beta-blocker	0.99 (0.93–1.05)	.64	0.98 (0.93–1.04)	.56
Evidence-based beta-blocker	0.94 (0.90–0.99)	.009	0.93 (0.89–0.98)	.005
Warfarin	1.01 (0.96–1.05)	.82	1.02 (0.97–1.06)	.47
Aldosterone antagonist	0.97 (0.92–1.01)	.16	0.97 (0.91–1.03)	.30
ICD	1.02 (0.95–1.09)	.53	1.02 (0.95–1.10)	.62
Disease management	1.01 (0.99–1.03)	.17	1.01 (1.00–1.03)	.15

Abbreviations: HR, hazard ratio; CI, confidence interval; ICD, implantable cardioverter-defibrillator.

^*Hazard ratios estimate the risk of the outcome dependent upon a 10% increase in hospital-level adherence.